- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03264677
An 8-week Full Face HUT Clinical Trial for HydroBoost (2.0/3.0)
An 8-week Full Face HUT Design, Single Center, Double Blinded, Controlled and Randomized Study to Evaluate Different Product Regimens' Performance on Protecting Skin With Resilience Under Tracked City Environmental Aggressors
- To investigate the product regiments' performance on moisturization related skin healthy signs (skin moisturization, barrier function, elasticity, translucency, roughness and skin conditions) through instrumental evaluation, clinical grading and self-assessment before, during and after 8 weeks' home usage under city environmental aggressors (Sun, change of temperature and humidity, wind and air pollution) among 3 product regimens and Non-treatment control;
- To explore the linkage among products efficacy, ambient aggressors, and life habits;
- To investigate product regimens' tolerance and safety via Home Use Test;
- To collect skin microflora/microbiome samples for potential research on skin microbiome distribution change as impacted by product application and/or environmental aggressors change (data will be analyzed and reported separately).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, double blinded, controlled and randomized 8-week home use clinical trial.
Subjects will be randomly and evenly divided into 3 groups (40subjects/group) with different facial care regimens during the 8-week home use study.
Group 1: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel Group 2: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel Group 3: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion There will be a 3-day wash-in period after subject's enrollment. During the period, no product will be allowed to be applied on the face and upper chest but only water washes twice per day in the morning and evening for 3 days before baseline (BL) measurement.
After baseline (BL) measurement, the product regimens will be applied on face at site under site instruction according to the randomization. Measurements will be taken at 2-4 hours and 8 hours after product regimens' application. Upper chest area will be measured as no treatment control.
A set of product regimen includes a facial cleanser and a facial cream will be distributed to each subject according to grouping and applied on the face at home for 8 weeks. Both cleanser and cream products will be applied twice a day in the morning and evening on the whole face. For the upper chest area, use water wash only twice per day in the morning and evening, no any other product is allowed.
The usage of assigned product regimens will be discontinued after 8-week home use, no any other product is allowed but only water wash twice per day in the morning and evening on both face and upper chest for 3 days (regression period).
Subjects will not be allowed to use sunscreen, makeup and any other cosmetic products on face and upper chest during the study period.
Subjects will visit the site at Screening (-3D), Baseline (BL), 1-week (1W), 4-week (4W), 8-week (8W) and 8-week+3-days (+3D) for measurements.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200443
- Shanghai Skin Disease Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Chinese Females aged 18 - 40 years old in good physical and mental condition;
- Self-perceived dry facial skin without lesions. Corneometer score ≤35 arbitrary units on both sides of cheek areas;
- Having daily routine skin exposure (out-door activities) to city environmental challenge and having concern on its impact to healthy skin signs (e.g. Smoothness, Firmness, Translucency, Trouble (pimple, acne) free, Plumpness, etc.);
- Willing to stay in Shanghai City during the whole study period without travel plan;
- Having mild to moderate pre-aging sign, e.g. fine line, roughness when skin is dry. Having skin dullness concern on the face;
- Non-regular body moisturizer user. Expose the upper-chest site during study;
- Willing to comply with the study instruction (see Appendix IX);
- Agree to use only water to wash face and upper chest, avoid using any cosmetic products (include but not limited to: wash/ soap/ moisturizer/ toner/ sparge/ sunscreen/ oil/ (water) mask/ scrub/ makeup/ fragrance/ light treatment/ massage, etc.) in the evening before each visit day. No washing on face and upper chest and no product application at home in the morning of the visit day. Subjects will wash the test areas when arrive the test site according to the site instruction;
- After enrollment, there will be a 3-day wash-in period, during which subjects agree to use water only to wash the face and upper chest twice per day in the morning and evening. Avoid using any cosmetic products as listed in above item 8 in both test areas;
- Then an 8-week home use period will follow, during which subjects agree to use the assigned product regimens (facial cleanser and facial cream) on face twice per day in the morning and evening. Use water only to wash the upper chest twice per day in the morning and evening. Avoid using any cosmetic products as listed in above item 8 in both test areas;
- After the 8-week home use of the assigned product regimens, subjects will stop using the products for 3 days (Regression period). Subjects agree to use water only to wash the face and upper chest twice per day in the morning and evening during the period. Avoid using any cosmetic products as listed in above item 8 in both test areas;
- Generally in good health based on medical history reported by the subject;
Female subjects must meet one of the following criteria:
Is not of child-bearing potential or is in a monogamous relationship with a partner who is not of child-bearing potential, meaning the subject and/or partner:
- Is post-menopausal (amenorrhea for at least 1 year),
- Had a surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal occlusion, hysterectomy, bilateral oophorectomy or salpingectomy)
Must agree to practice a medically acceptable form of birth control during the study and for 30 days after study completion. Female subjects must have used such birth control for at least 3 months prior to study start. Medically acceptable forms of birth control that may be used by the subject and/or partner include:
- Established use of hormonal methods of contraception (oral, injected, implanted, hormone patch or vaginal ring).
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps),
- Intrauterine device or intrauterine system,
- Abstinence from intercourse that could cause pregnancy. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- Is not a ward of the court or deprived from liberty by a judiciary or administrative decision;
- Able to read, write, speak and understand Chinese language or able to speak and understand Chinese language and accompanied by an impartial witness who can read, write, speak and understand Chinese language;
- Individual that has signed the Consent for Photograph Release (7-8 subjects/group) and ICD including portable tracker using and reporting as instruction;
Exclusion Criteria
- Participated in any cosmetic clinical test involving facial and/or body product application within 3 months before enrollment.
- Has known allergies or adverse reactions to common topical skincare products;
- Presents with a skin condition that may influence the outcome of the study (e.g., psoriasis, eczema, melanomas), primary/secondary lesions on test sites (e.g. erythema, scars, ulcers, vesicles);
- Has a self-reported uncontrolled metabolic condition or disease, such as diabetes, hypertension, hyper/hypothyroidism, hypercholesterolemia, asthma, epilepsy, etc. Individuals with a controlled health condition may also be excluded from the study at the discretion of the PI, if medically qualified, or the designated study physician;
- Is taking medication for a chronic condition (e.g., insulin, antihistamines, steroidal and non-steroidal anti-inflammatory drugs, antibiotics, etc.) or is taking any other medication that could influence the study results and/or affect the individual's safety, within 30 days before inclusion or during the study;
- Is taking immunosuppressive drugs within 3 months before inclusion and during the study;
- Has a history of or concurrent health condition/situation which, in the opinion of the PI, if medically qualified, or the designated study physician, may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study;
- Is simultaneously participating in any other type of clinical study;
- Is an employee/contractor or immediate family member of the PI, Study Site staff or Sponsor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
|
NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
Other Names:
|
Experimental: Group 2
NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
|
NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
Other Names:
|
Experimental: Group 3
NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
|
NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin surface moisture content
Time Frame: 9 weeks
|
Skin surface moisture content is measured by skin capacitance measurement.
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: 9 weeks
|
In this study, an evaluation tool will be used to measure and quantify skin dryness related Quality of Life (QoL) attributes, to get an understanding of the improvement (related to moisturization benefits) after treatment of skin care regimens
|
9 weeks
|
Subject Self-assessment
Time Frame: 9 weeks
|
Subject self-assessment Questionnaire (QN) on product performance
|
9 weeks
|
Temperature
Time Frame: 9 weeks
|
Individual temperature measured by portable environmental tracker
|
9 weeks
|
Humidity
Time Frame: 9 weeks
|
Individual humidity measured by portable environmental tracker
|
9 weeks
|
PM 2.5
Time Frame: 9 weeks
|
Individual PM 2.5 measured by portable environmental tracker
|
9 weeks
|
Skin microbiome
Time Frame: 9 weeks
|
To collect skin microflora/microbiome samples for potential research on skin microbiome distribution change as impacted by product application and/or environmental aggressors change.
|
9 weeks
|
Life habits
Time Frame: 9 weeks
|
Subject's life pattern captured by diary.
|
9 weeks
|
Skin barrier function
Time Frame: 9 weeks
|
TEWL
|
9 weeks
|
Skin elasticity
Time Frame: 9 weeks
|
The mechanical property of the epidermis is measured by a non-invasive, in vivo suction skin elasticity meter.
|
9 weeks
|
Skin roughness
Time Frame: 9 weeks
|
Skin roughness measurement via skin surface imaging
|
9 weeks
|
Skin translucency
Time Frame: 9 weeks
|
Many common materials transmit and scatter light but are neither transparent or opaque.
Such materials are described as translucent and the degree of translucency depends on the absorption and scattering coefficients of the material.
In this study, the degree of skin translucency is quantified by the rate of lateral scatter of light and the total amount of backscattered light, which captured by a non-invasive Translucency Meter probe.
|
9 weeks
|
Skin deep layer moisture content
Time Frame: 9 weeks
|
Skin deep layer moisture content by measuring skin dielectric constant.
|
9 weeks
|
Skin firmness
Time Frame: 9 weeks
|
Dermatologist grading of skin firmness
|
9 weeks
|
Skin elasticity
Time Frame: 9 weeks
|
Dermatologist grading of skin elasticity
|
9 weeks
|
Skin radiance
Time Frame: 9 weeks
|
Dermatologist grading of skin radiance
|
9 weeks
|
Skin smoothness
Time Frame: 9 weeks
|
Dermatologist grading of skin smoothness
|
9 weeks
|
Skin fine lines
Time Frame: 9 weeks
|
Dermatologist grading of skin fine lines
|
9 weeks
|
Skin softness
Time Frame: 9 weeks
|
Dermatologist grading of skin softness
|
9 weeks
|
Skin hydration
Time Frame: 9 weeks
|
Dermatologist grading of skin hydration
|
9 weeks
|
Skin translucency
Time Frame: 9 weeks
|
Dermatologist grading of skin translucency
|
9 weeks
|
Pimple
Time Frame: 9 weeks
|
Dermatologist grading of pimple
|
9 weeks
|
Clogged pores
Time Frame: 9 weeks
|
Dermatologist grading of clogged Pores
|
9 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chao Yuan, Shanghai Skin Disease Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CO-170223145432-SACT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Skin Healthy Signs
-
JemincareZhejiang Hangyu Pharmaceutical Co., LtdNot yet recruiting
-
Jeil Pharmaceutical Co., Ltd.CompletedHealthy AdultKorea, Republic of
-
Alessandro HaupenthalSanta Catarina Federal UniversityUnknown
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
National Cheng-Kung University HospitalCompleted
-
Yonsei UniversityCompleted
-
BeiGeneNot yet recruitingAutoimmune Diseases | Healthy Volunteers | Healthy Subjects | Healthy Participants | Healthy Adult Participants
-
Yonsei UniversityNot yet recruiting
-
Jeil Pharmaceutical Co., Ltd.CompletedHealthy AdultKorea, Republic of
-
Jeil Pharmaceutical Co., Ltd.CompletedHealthy AdultKorea, Republic of
Clinical Trials on Group 1
-
Oslo University HospitalNorwegian Fund for Postgraduate Training in PhysiotherapyCompletedHealth-Related Quality of LifeNorway
-
Arkansas Children's Hospital Research InstituteRecruiting
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.CompletedModerate to Severe Atopic DermatitisUnited States, Canada, Czechia, Germany, Poland
-
Marmara UniversityCompletedStair up and Down, Amputation | Amputation,Stair up and DownTurkey
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownRetinal Detachment | High Myopia | Macular HolesChina
-
Biruni UniversityCompleted
-
Weill Medical College of Cornell UniversityTerminatedChronic Obstructive Pulmonary Disease | COPDUnited States
-
Biotronik SE & Co. KGBiotronik Japan, Inc.RecruitingImplantable Cardioverter Defibrillator(ICD)Japan
-
Riphah International UniversityCompleted
-
Hospital Universitario Central de AsturiasRecruiting